Systemic treatment of metastatic breast cancer
- 1 May 2001
- journal article
- review article
- Published by Mark Allen Group in Hospital Medicine
- Vol. 62 (5) , 289-295
- https://doi.org/10.12968/hosp.2001.62.5.1573
Abstract
This article reviews recent advances in the treatment of metastatic breast cancer, in particular the results of randomized controlled phase III clinical trials. These have led to the evidence-based introduction of several new drugs including aromatase inhibitors, taxanes and bisphosphonates, some of which have been shown to impact on overall survival.Keywords
This publication has 28 references indexed in Scilit:
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Conventional-Dose Chemotherapy Compared with High-Dose Chemotherapy plus Autologous Hematopoietic Stem-Cell Transplantation for Metastatic Breast CancerNew England Journal of Medicine, 2000
- British Association of Surgical Oncology Guidelines: The management of metastatic bone disease in the United KingdomEuropean Journal of Surgical Oncology, 1999
- Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone MetastasesNew England Journal of Medicine, 1996
- Second-line chemotherapy for metastatic breast cancer including quality of life issuesThe Breast, 1996
- Chemotherapy of advanced breast cancer: the place of active new drugsThe Breast, 1996
- Treatment of relapse of breast cancer after adjuvant systemic therapy — Review and guidelines for future researchEuropean Journal Of Cancer, 1994
- The influence of adjuvant chemotherapy on outcome after relapse for patients with breast cancerEuropean Journal Of Cancer, 1993
- The influence of chemotherapy on survival after recurrence in breast cancer—a population-based study of patients treated in the 1950s, 1960s and 1970sEuropean Journal Of Cancer, 1993
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987